1. Home
  2. ENTA vs EPRX Comparison

ENTA vs EPRX Comparison

Compare ENTA & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • EPRX
  • Stock Information
  • Founded
  • ENTA 1995
  • EPRX 2011
  • Country
  • ENTA United States
  • EPRX Canada
  • Employees
  • ENTA N/A
  • EPRX N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • EPRX
  • Sector
  • ENTA Health Care
  • EPRX
  • Exchange
  • ENTA Nasdaq
  • EPRX NYSE
  • Market Cap
  • ENTA 160.3M
  • EPRX 137.7M
  • IPO Year
  • ENTA 2013
  • EPRX N/A
  • Fundamental
  • Price
  • ENTA $7.28
  • EPRX $4.32
  • Analyst Decision
  • ENTA Buy
  • EPRX Strong Buy
  • Analyst Count
  • ENTA 4
  • EPRX 1
  • Target Price
  • ENTA $18.00
  • EPRX $9.00
  • AVG Volume (30 Days)
  • ENTA 168.6K
  • EPRX 14.5K
  • Earning Date
  • ENTA 08-04-2025
  • EPRX 08-07-2025
  • Dividend Yield
  • ENTA N/A
  • EPRX N/A
  • EPS Growth
  • ENTA N/A
  • EPRX N/A
  • EPS
  • ENTA N/A
  • EPRX N/A
  • Revenue
  • ENTA $64,462,999.00
  • EPRX N/A
  • Revenue This Year
  • ENTA N/A
  • EPRX N/A
  • Revenue Next Year
  • ENTA $0.48
  • EPRX N/A
  • P/E Ratio
  • ENTA N/A
  • EPRX N/A
  • Revenue Growth
  • ENTA N/A
  • EPRX N/A
  • 52 Week Low
  • ENTA $4.09
  • EPRX $2.20
  • 52 Week High
  • ENTA $17.24
  • EPRX $4.49
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 60.14
  • EPRX N/A
  • Support Level
  • ENTA $6.87
  • EPRX N/A
  • Resistance Level
  • ENTA $8.47
  • EPRX N/A
  • Average True Range (ATR)
  • ENTA 0.50
  • EPRX 0.00
  • MACD
  • ENTA -0.03
  • EPRX 0.00
  • Stochastic Oscillator
  • ENTA 54.44
  • EPRX 0.00

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About EPRX EUPRAXIA PHARMACEUTICALS INC

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.

Share on Social Networks: